2024年,吉利德堪称水逆王者。重金收购的Trodelvy,在非小细胞肺癌和尿路上皮癌的三期临床试验中接连失利,并撤回尿路上皮癌适应症的加速批准,一度被贴上“水逆”标签。戏剧性的是,在2025年,这款Trop2 ADC却在三阴性乳腺癌(TNBC)领域接连取胜:2025年4月21日,Trodelvy联合K药一线治疗转移性TNBC的ASCENT-04试验成功;5月23日,单药一线治疗PD-L1阴性...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.